The antitumor effects of anti-PD-1 antibody against mismatch repair deficiency (MMR-D)-associated cancers have been reported. MMR-D is found in approximately 20%-30% of endometrial carcinomas (ECs) and frequently occurs due to MLH1 promoter hypermethylation (MLH1-PHM). ECs with MLH1-PHM are classified according to the molecular screening of Lynch syndrome (LS), but few detailed reports are available. The purpose of this study was to clarify the clinical features of EC with MLH1-PHM.

中文翻译：

---

MLH1 启动子高甲基化预测错配修复缺陷子宫内膜癌的预后较差。

已经报道了抗 PD-1 抗体对错配修复缺陷 (MMR-D) 相关癌症的抗肿瘤作用。MMR-D 存在于大约 20%-30% 的子宫内膜癌 (EC) 中，并且由于MLH1启动子高甲基化 ( MLH1 -PHM) 而经常发生。具有MLH1 -PHM 的 EC 根据 Lynch 综合征 (LS) 的分子筛查进行分类，但很少有详细的报告可用。本研究的目的是阐明 EC 与MLH1 -PHM 的临床特征。